Astral Codex Ten

European Commission

3 min read

European Commission

Article

European Commission is a recurring organization in the Astral Codex Ten archive, appearing 2 times across 2 issues between November 04, 2021 and January 27, 2022. The archive places it in contexts such as “When the European Parliament or the European Commission has challenged Orbán’s government”; “the European Commission does drug approvals for all of the EU”. It most often appears alongside Europe, Germany, ACA.

Metadata

  • Category: Organizations
  • Mention count: 2
  • Issue count: 2
  • First seen: November 04, 2021
  • Last seen: January 27, 2022

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

Dictator Book Club: Orban
November 04, 2021 · Original source
For the past seven years, Orbán has used a maneuver that he has called the “dance of the peacock.” His government would insert measures into new laws precisely for the purpose of removing them. “He’ll generally put in one outrageous thing and one super-outrageous thing,” Kim Lane Scheppele, a legal scholar at Princeton who studies Hungary, told me. “But the super-outrageous thing isn’t really necessary—it’s designed to be jettisoned.” When the European Parliament or the European Commission has challenged Orbán’s government on the antidemocratic measures, he has made a few symbolic gestures of conciliation, “as if,” he has said, “we would like to make friends with them.”
Highlights From The Comments On Health Care Systems
January 27, 2022 · Original source
One of the other major differences between the US healthcare system and the EU systems is that the European Commission does drug approvals for all of the EU (and there are other EU-wide paths to getting drugs approved, with approval by any regulatory body being sufficient for the drug to be approved); whereas, the FDA does approvals for just the US (and it doesn't compete with any other US regulators to do the approvals). This gives individual European countries much more leverage than the US would have for negotiating with drug manufacturers. Since most of the cost of drug manufacturing is the research, trials, and approval process, Norway (technically a non-EU member of the EEA, but they still accept approvals given by the European Commission) can offer drugmakers relatively low prices and still have them sell their drugs there because they're already going through the European Commission approval process to sell their drugs in the rest of Europe. If the USA starts setting drug prices particularly low, it will have a much bigger impact on the incentive to fund drug trials through the FDA approval process. This also changes the optics dramatically. There's not going to be a scandal over a drugmaker failing to push their drugs through the approval process the same way there would be over it refusing to sell drugs to a particular country where those drugs are approved. (And I think it's generally accepted that the FDA's process is slower, more stringent, and more expensive than Europe's.)